Stocks · News reference
Embecta (NASDAQ:EMBC) raises FY2026 Adj EPS guidance from $1.55-$1.75 to $1.80-$1.90 vs $1.59 analyst estimate. Affirms FY2026 sales outlook from $1.015 billion-$1.035 billion to $1.015 billion-$1.035 billion vs $1.021
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Embecta Corp. (EMBC) announced that management will participate in investor events at the Wells Fargo 2026 Healthcare Conference on September 9, 2026, in Boston and the J.P. Morgan 4th Annual Nashville Healthcare Conference 2026 on September 10, 2026, where they will host fireside chats and one-on-one investor meetings.
Gainers AVITA Medical (NASDAQ:RCEL) stock rose 58.4% to $7.53 during Friday's regular session. The company's market cap stands at $146.1 million. As per the press release, Q2 earnings came out yesterday.
Embecta Corp. (NASDAQ: EMBC), a global medical supplies company with a 100-year legacy in insulin delivery, announced its third quarter fiscal 2026 financial results on August 7, 2026. The company hosted a conference call and webcast for analysts and investors to discuss the earnings.